Question to the Department of Health and Social Care:

To ask His Majesty's Government what evidence they have received from industry of the impending impact on UK Research and Development investment of rising payment rates under the voluntary and statutory schemes for branded medicines.

The Department has received materials from pharmaceutical industry Trade Associations and from individual companies about the impact of payment percentages under the voluntary and statutory schemes.

These include responses to the assessment made by the Department in the draft impact assessment that accompanies our recent consultation on increased rates in the statutory scheme. We will be considering this evidence over the coming weeks and will publish our response alongside the final impact assessment.